Publications

Papers are continually published using the SEARCH Database. For questions or collaboration opportunities, please contact us.

PAPERS | ABSTRACTS

1.Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr., Terris MK, and Aronson WJ. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002 Oct;60(4):670-4

2.Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ. Comparison of pre-operative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy .J Urol. 2003 Mar;169(3):969-73.

3.Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Dorey F, and Terris MK. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003 Apr;61(4):736-41.

4.Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Terris MK. Comparison of percent of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence following radical prostatectomy .Urology. 2003 Apr;61(4):742-7.

5.Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer .J Urol. 2003 Jun;169(6):2129-35.

6.Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of prostate specific antigen recurrence following radical prostatectomy .J Urol. 2003 Jun;169(6):2136-41

7.Freedland SJ, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003 Jun;169(6):2142-6.

8.Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percentage of prostate needle biopsy cores with carcinoma from the most involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy .Cancer. 2003 Dec 1;98(11):2344-50.

9.Freedland SJ, Amling CL, Terris MK, Presti JC Jr, Aronson WJ, Elashoff D, and Kane CJ. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH Database. Prostate Cancer Prostatic Dis. 2003;6(3):261-5

10.Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, and Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer. J Clin Oncol. 2004 Feb 1;22(3):446-53. Epub 2003 Dec 22.

11.Freedland SJ, Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, and Amling CL. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar;63(3):518-22.

12.Freedland SJ, Aronson WJ, Presti JC Jr. , Amling CL, Terris MK, Trock B, and Kane CJ. Predictors of prostate specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004 Apr 15;100(8):1633-8.

13.Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson WJ. Pre-operative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum prostate specific antigen. J Urol. 2004 Jun;171(6 Pt 1):2215-20

14.Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Biochemical outcome after radical prostatectomy among men with normal pre-operative serum prostate specific antigen levels. Cancer. 2004 Aug 15;101(4):748-53

15.Freedland SJ, Terris MK, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Aronson WJ. Obesity and biochemical outcome following radical prostatectomy for organ-confined disease with negative surgical margins. J Urol. 2004 Aug;172(2):520-4

16.Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr., and Terris MK. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Can Res 2005; 11: 7735-7742

17.Freedland SJ, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr., and Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer, and biochemical progression after radical prostatectomy. J Clin Oncol. 2005 Nov 1;11(21):7735-42.

18.Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. J Urol. 2006 Feb;175(2):500-4; discussion 504.

19.Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. J Urol. J Urol. 2006 Apr;175(4):1298-302; discussion 1302-3.

20.Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC Jr., Mangold LA, Humphreys E, Epstein JI, Partin AW, and Freedland SJ. Clinical and pathological outcome after radical prostatectomy for prostate cancer with a preoperative Gleason sum 8 to 10. Cancer. 2006 Sep 15;107(6):1265-72

21.Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti, JC, Jr., Amling CL, Terris MK, Aronson WA, Kane CJ, and Carroll PR. Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence following radical prostatectomy. Cancer. 2006 Nov 15;107(10):2384-91.1

22.Fitzsimons NJ, Presti JC Jr., Kane CJ, Terris MK, Aronson WJ, Amling CL, and Freedland SJ. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol. 2006 Dec;176(6 Pt 1):2453-8; discussion 2458

23.Kane CJ, Presti JC Jr., Amling CL, Aronson WJ, Terris MT, and Freedland SJ. Changing nature of high-risk patients undergoing radical prostatectomy. J Urol. 2007 Jan;177(1):113-7

24.King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC, Jr. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from the SEARCH database. Urology. 2007 Apr;69(4):732-7.

25.King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ and Presti JC, Jr.. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report by the SEARCH database study group. Urology. 2007 May;69(5):921-6

26.Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MT, and Presti JC Jr. Upgrading and downgrading of prostate needle biopsies: risk factors and clinical implications. Urology. Urology. 2007 Jun;69(6):1138-42.

27.Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, T Aronson WJ, Presti JC Jr., Mangold LA, and Freedland SJ. Do racial differences in prostate size explain higher serum PSA concentrations among black men? Urology. 2007 Jun;69(6):1138-42

28.Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, Presti JC Jr, Aronson WJ, Freedland SJ. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol. 2007 Sep;178(3 Pt 1):990-5. Epub 2007 Jul 16.

29.Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and Freedland SJ. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score. Urology. 2007 Aug;70(2):277-82.

30.Scales CD Jr., Presti JC Jr., Kane CJ, Terris MK, Aronson WJ, Amling CL, and Freedland SJ. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy J Urol. 2007 Oct;178(4 Pt 1):1249-52. Epub 2007 Aug 14.

31.Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, and Amling CL. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes Eur Urol. 2008 Apr;53(4):758-64; discussion 765-6. Epub 2007 Aug 31.

32.Buschemeyer WC III, Hamilton RJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the PSA era? J Urol. 2008 Jan;179(1):124-9; discussion 129. Epub 2007 Nov 12

33.Hamilton RJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and Freedland SJ. Race, biochemical recurrence, and PSADT after radical prostatectomy .Cancer. 2007 Nov 15;110(10):2202-9

34.Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, and Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21;298(19):2275-80

35.Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson I, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, and Freedland SJ. Are the Partin tables accurate for African-American men in the United States? Urology. 2008 Jan;71(1):151-5. doi: 10.1016/j.urology.2007.08.016

36.Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and Freedland SJ. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy .J Urol. 2008 Feb;179(2):523-7; discussion 527-8

37.Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and Freedland SJ. Limitations of PSADT following biochemical recurrence after radical prostatectomy .J Urol. 2008 May;179(5):1785-9; discussion 1789-90. doi: 10.1016/j.juro.2008.01.040. Epub 2008 Mar 17

38.Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, and Kane CJ. Nerve sparing does not increase the risk of biochemical recurrence .Prostate Cancer Prostatic Dis. 2009;12(2):172-6. doi: 10.1038/pcan.2008.40. Epub 2008 Jul 15

39.Jayachandran J, Bañez LL, Levy D, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and Freedland SJ. Risk stratification for biochemical recurrence among men with positive surgical margins or extracapsular disease after radical prostatectomy .BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

40.Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, and Aronson WJ. Obesity and oncological outcome after radical prostatectomy: impact of PSA-based prostate cancer screening: results from the SEARCH and Duke Prostate Center databases.BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7

41.Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and Freedland SJ. What are the factors associated with a short PSA doubling time? J Urol. 2008 Nov;180(5):1980-4; discussion 1985. doi: 10.1016/j.juro.2008.07.031. Epub 2008 Sep 17.

42.Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and Freedland SJ. Obesity and positive surgical margins by anatomic location after radical prostatectomy .BJU Int. 2008 Sep;102(8):964-8. doi: 10.1111/j.1464-410X.2008.07881.x. Epub 2008 Jul 7

43.Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC Jr., Amling CL, and Freedland SJ. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained .BJU Int. 2008 Nov;102(9):1074-9. doi: 10.1111/j.1464-410X.2008.08015.x. Epub 2008 Sep 3.

44.Schroeck FR, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and Freedland SJ. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int. 2009 Mar;103(5):603-8. doi: 10.1111/j.1464-410X.2008.08118.x. Epub 2008 Nov 18.

45.Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, and Terris MK. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. 2009 May;103(9):1168-72. doi: 10.1111/j.1464-410X.2009.08405.x. Epub 2009 Mar 6.

46.Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, and Freedland SJ. Preoperative predictors of blood loss at the time of radical prostatectomy .Prostate Cancer Prostatic Dis. 2009;12(3):264-8. doi: 10.1038/pcan.2009.6. Epub 2009 Mar 24

47.Moreira DM, Jayachandran J, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, and Freedland SJ. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy .BJU Int. 2009 Nov;104(10):1452-6. doi: 10.1111/j.1464-410X.2009.08623.x. Epub 2009 May 18

48.Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Amling CL, and Freedland SJ. Race and time from diagnosis to radical prostatectomy: does equal-access mean equal timely access to the operating room? – results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1208-12. doi: 10.1158/1055-9965.EPI-08-0502. Epub 2009 Mar 31

49.Teeter AE, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Does early PSADT, calculated starting at the first detectable PSA after radical prostatectomy, correlate with standard PSADT?—a report from the SEARCH database group. BJU Int. 2009 Dec;104(11):1604-9. doi: 10.1111/j.1464-410X.2009.08680.x. Epub 2009 Jun 22.

50.Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy BJU Int. 2010 Jan;105(1):28-33. doi: 10.1111/j.1464-410X.2009.08684.x. Epub 2009 Jun 12

51.Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, and Freedland SJ. Estimated blood loss as a predictor of PSA recurrence .BJU Int. 2010 Feb;105(3):347-51. doi: 10.1111/j.1464-410X.2009.08792.x. Epub 2009 Aug 25.

52.Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Natural history of patients with persistently elevated PSA after radical prostatectomy.J Urol. 2009 Nov;182(5):2250-5. doi: 10.1016/j.juro.2009.07.022. Epub 2009 Sep 16.

53.Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr. Freedom from a detectable ultrasensitive PSA at two years after radical prostatectomy predicts a favorable clinical outcome: Urology. 2010 Feb;75(2):439-44. doi: 10.1016/j.urology.2009.06.089. Epub 2009 Oct 12.

54.Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, and Freedland SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy.Prostate Cancer Prostatic Dis. 2010 Mar;13(1):87-93. doi: 10.1038/pcan.2009.48. Epub 2009 Nov 17.

55.Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy .BJU Int. 2010 Jun;105(11):1541-7. doi: 10.1111/j.1464-410X.2009.09016.x. Epub 2009 Nov 12.

56.Jayachandran J, Bañez LL, Levy D, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and Freedland SJ. Obesity as a predictor of adverse outcome across black and white race: results from the shared equal access regional cancer hospital (SEARCH) database. Cancer. 2009 Nov 15;115(22):5263-71. doi: 10.1002/cncr.24571.

57.Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, and Freedland SJ. Body mass index and prostate specific antigen as a predictor of adverse pathology of prostate cancer and biochemical recurrence following radical prostatectomy. J Urol 2009; 182: 491-496

58.Jayachandran J, Aronson WJ, Terris MK, Presti JC, Jr., Amling CL, Kane CJ, and Freedland SJ. Diabetes and outcomes after radical prostatectomy – are results affected by obesity and race? Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):9-17. doi: 10.1158/1055-9965.EPI-09-0777.

59.Bañez LL, Loftis RM, Freedland SJ, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, and Terris MK. The influence of hepatic dysfunction on prostate cancer outcomes following radical prostatectomy. Prostate Cancer Prostatic Dis. 2010 Jun;13(2):173-7. doi: 10.1038/pcan.2010.3. Epub 2010 Mar 2.

60.Kane CJ, Im R, Amling CL, Presti JC Jr., Aronson WJ, Terris MK, and Freedland SJ. Outcomes after radical prostatectomy among men who are candidates for active surveillance .Urology. 2010 Sep;76(3):695-700. doi: 10.1016/j.urology.2009.12.073. Epub 2010 Apr 15.

61.Hamilton RJ, Bañez LL, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr., Amling CL, and Freedland SJ. Statin medication use and the risk of biochemical recurrence following radical prostatectomy Cancer .Cancer. 2010 Jul 15;116(14):3389-98. doi: 10.1002/cncr.25308.

62.Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC, Jr., Kane CJ, Amling CL, Freedland SJ. Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the shared equal access regional cancer hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2011 Dec;14(4):361-6. doi: 10.1038/pcan.2011.42. Epub 2011 Sep 6

63.Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Postoperative PSA nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy .Int J Urol. 2010 Nov;17(11):914-22. doi: 10.1111/j.1442-2042.2010.02631.x. Epub 2010 Sep 30.

64.Kim H, Moreira DM, Smith MR, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. A natural history of weight change in men with prostate cancer on androgen deprivation therapy .BJU Int. 2011 Mar;107(6):924-8. doi: 10.1111/j.1464-410X.2010.09679.x. Epub 2010 Sep 22.

65.Kim H, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Glycemic control and prostate cancer progression .Prostate. 2010 Oct 1;70(14):1540-6. doi: 10.1002/pros.21189.

66.Moreira DM, Antonelli JA, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy .Urology. 2010 Nov;76(5):1218-23. doi: 10.1016/j.urology.2010.01.066. Epub 2010 Apr 9.

67.Teeter AE, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Does PSADT after radical prostatectomy correlate with overall survival and prostate cancer-specific mortality? Urology. 2011 Jan;77(1):149-53. doi: 10.1016/j.urology.2010.04.071. Epub 2010 Dec 8.

68.Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and Freedland SJ. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy .BJU Intl 2012; 110: 492-49

69.Chu DI, Moreira DM, Gerber L, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access healthcare setting .Cancer. 2012 Oct 15;118(20):4999-5007. doi: 10.1002/cncr.27456. Epub 2012 Mar 13.7

70.Muller RL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Urology. 2012 May;79(5):1105-10. doi: 10.1016/j.urology.2012.01.034. Epub 2012 Mar 23.

71.Kopp R, Stroup SP, Schroeck F, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC Jr., Amling CL, and Kane CJ. Are repeat biopsies safe? A cohort analysis from the SEARCH Database. J Urol. 2012 Jun;187(6):2056-60. doi: 10.1016/j.juro.2012.01.083. Epub 2012 Apr 11

72.Ho T, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, and Freedland SJ Obesity, PSA nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Eur Urol. 2012 Nov;62(5):910-6. doi: 10.1016/j.eururo.2012.08.015. Epub 2012 Aug 20.

73.Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC. Jr, Amling CL, and Freedland SJ. Delayed radical prostatectomy in intermediate-risk prostate cancer decreases time to biochemical recurrence .Prostate. 2013 Mar;73(4):409-17. doi: 10.1002/pros.22582. Epub 2012 Sep 19.

74.Keto CJ, Aronson WJ, Terris MK, Presti JC Jr. Kane CJ, Amling CL, and Freedland SJ. Detectable PSA nadir during androgen deprivation therapy predicts adverse prostate cancer specific outcomes .Eur Urol. 2014 Mar;65(3):620-7. doi: 10.1016/j.eururo.2012.11.052. Epub 2012 Dec 6.

75.Wu C, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, and Freedland SJ. Diabetes predicts metastasis after radical prostatectomy, but only in obese men .BJU Int. 2013 Jun;111(8):E310-8. doi: 10.1111/j.1464-410X.2012.11687.x. Epub 2013 Jan 10

76.Punnen S, Freedland SJ, Presti, JC, Jr., Aronson WA, Terris MK, Kane CJ, Amling CL, Carroll PR, and Cooperberg MR. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun;65(6):1171-7. doi: 10.1016/j.eururo.2013.03.058. Epub 2013 Apr 8.

77.Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. High serum folate is associated with reduced biochemical recurrence after radical prostatectomy .Int Braz J Urol. 2013 May-Jun;39(3):312-8; discussion 319. doi: 10.1590/S1677-5538.IBJU.2013.03.03

78.Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? Urology. 2013 Jul;82(1):53-8. doi: 10.1016/j.urology.2012.10.090.

79.Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, and Freedland SJ. Metformin does not affect risk of biochemical recurrence following radical prostatectomy .Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7. doi: 10.1038/pcan.2013.48. Epub 2013 Oct 8

80.Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, and Freedland SJ. Cigarette smoking is associated with increased risk for biochemical recurrence, metastasis, castration-resistant prostate cancer and mortality after radical prostatectomy .Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11

81.Moreira DM, Cooperberg MR, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Kuchibhatla M, and Freedland SJ. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naïve men and patients receiving androgen deprivation therapy .Prostate Cancer Prostatic Dis. 2014 Mar;17(1):91-6. doi: 10.1038/pcan.2013.59. Epub 2014 Jan 14

82.Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, and Freedland SJ. The impact of pathologic staging on the long term oncologic outcomes of clinically high risk prostate cancer. Cancer. 2014 Jun 1;120(11):1656-62. doi: 10.1002/cncr.28647. Epub 2014 Mar 19.

83.Allott EA, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy .BJU Int. 2014 Nov;114(5):661-6. doi: 10.1111/bju.12720. Epub 2014 May 8.;

84.Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Serum lipid profile and risk of prostate cancer recurrence .Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2349-56. doi: 10.1158/1055-9965.EPI-14-0458. Epub 2014 Oct 10

85.Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BR, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. Practice patterns and predictors of follow-up imaging after a negative bone scan in men with CRPC .J Urol. 2015 Apr;193(4):1232-8. doi: 10.1016/j.juro.2014.11.014. Epub 2014 Nov 13.

86.Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2C prostate cancer intermediate or high-risk disease? Cancer. 2015 May 1;121(9):1414-21. doi: 10.1002/cncr.29147. Epub 2014 Dec 9.

87.Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. PSA, Stage, or Gleason Score: Which is best for predicting outcomes after radical prostatectomy and does it vary by the outcome being measured? Int J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015 Feb 24.

88.Zapata DF, Howard LE ,Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, and Freedland SJ. Smoking is a predictor of adverse pathological features at radical prostatectomy .Int J Urol. 2015 Jul;22(7):658-62. doi: 10.1111/iju.12773. Epub 2015 Apr 14.

89.Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul;33(7):329.e1-6. doi: 10.1016/j.urolonc.2015.04.012. Epub 2015 May 18.

90.Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):333-7. doi: 10.1038/pcan.2015.25. Epub 2015 May 26.;

91.McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy.Int J Urol. 2016 Mar;23(3):241-6. doi: 10.1111/iju.13027. Epub 2015 Dec 14.

92.Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb;117(2):244-8. doi: 10.1111/bju.13181. Epub 2015 Jun 23.

93.Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 Jun;117(6):897-903. doi: 10.1111/bju.13182. Epub 2015 Jun 23.

94.Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P and Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy. Cancer. 2015 Dec 1;121(23):4272. doi: 10.1002/cncr.29668. Epub 2015 Sep 3.

95.Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer-Results from the SEARCH database. Cancer Epidemiol. 2015 Dec;39(6):1066-70. doi: 10.1016/j.canep.2015.09.007. Epub 2015 Oct 6.

96.Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 Aug;118(2):250-7. doi: 10.1111/bju.13319. Epub 2015 Oct 8.;

97.Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15;122(2):222-9. doi: 10.1002/cncr.29748. Epub 2015 Oct 20

98.Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence .Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):547-54. doi: 10.1158/1055-9965.EPI-15-0876. Epub 2016 Jan 25.

99.Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK5, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct;118(4):570-7. doi: 10.1111/bju.13405. Epub 2016 Feb 8.

100.Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct;96:171-176. doi: 10.1016/j.urology.2016.06.011. Epub 2016 Jun 16.

101.Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 Nov;196(5):1408-1414. doi: 10.1016/j.juro.2016.06.086. Epub 2016 Jun 25.

102.Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 Nov;196(5):1408-1414. doi: 10.1016/j.juro.2016.06.086. Epub 2016 Jun 25

103.Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? .Prostate Cancer Prostatic Dis. 2016 Dec;19(4):380-384. doi: 10.1038/pcan.2016.26. Epub 2016 Jul 5.

104.Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Dec 15;122(24):3848-3855. doi: 10.1002/cncr.30221. Epub 2016 Aug 9.

105.Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases?. Eur Urol Focus. 2016 Aug 29. pii: S2405-4569(16)30115-8. doi: 10.1016/j.euf.2016.08.007 ;

106.Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer.Clin Genitourin Cancer. 2017 Feb;15(1):60-66.e2. doi: 10.1016/j.clgc.2016.08.018. Epub 2016 Aug 31.

107.Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy Prostate. Prostate. 2017 Feb;77(2):154-163. doi: 10.1002/pros.23255. Epub 2016 Sep 29.

108.Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):72-78. doi: 10.1038/pcan.2016.47. Epub 2016 Oct 4.

109.Wadhwa H, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):423-428. doi: 10.1038/pcan.2016.45. Epub 2016 Oct 4.

110.Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.

111.Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 Nov;120(5B):E80-E86. doi: 10.1111/bju.13856. Epub 2017 Apr 30.

112.McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ.Characterization of a “low-risk” cohort of grade group 2 prostate cancer patients. Int J Urol. 2017 Aug;24(8):611-617. doi: 10.1111/iju.13387. Epub 2017 Jun 6.

113.Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29.

114.Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ .Race and risk of metastases and survival after radical prostatectomy. Cancer. 2017 Nov 1;123(21):4199-4206. doi: 10.1002/cncr.30834. Epub 2017 Jun 27.

115.Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 Dec;198(6):1309-1315. doi: 10.1016/j.juro.2017.07.009. Epub 2017 Jul 11.

116.Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ .Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol. 2017 Aug;24(8):618-623. doi: 10.1111/iju.13393. Epub 2017 Jul 11.

117.Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ.Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct;108:129-134. doi: 10.1016/j.urology.2017.07.009. Epub 2017 Jul 19.

118.Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes?. J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.08.107.

119.Zumsteg ZS1,Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy. Prostate. 2017 Dec;77(16):1592-1600. doi: 10.1002/pros.23436. Epub 2017 Oct 10.

120.McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 May;36(5):239.e17-239.e25. doi: 10.1016/j.urolonc.2018.01.005. Epub 2018 Feb 9.

121.Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Feb 23. doi: 10.1111/bju.14178.

122.Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Jul;122(1):76-82. doi: 10.1111/bju.14193. Epub 2018 Apr 10.

123.Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.

Back to Top

ABSTRACTS | PAPERS

1. Terris MK, Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr., and Aronson WJ. Race as an outcome predictor following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. AUA National Meeting, 2002

2. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Amling CL, Dorey F, and Aronson WJ. Pre-operative PSA density improves risk stratification for biochemical recurrence following radical prostatectomy AUA Western Section Meeting, 2002

3. Freedland SJ, Amling CL, Aronson WJ, Dorey F, Kane CJ, Presti JC Jr., and Terris MK. Time trends in biochemical recurrence following radical prostatectomy: Results of the SEARCH Database. AUA Western Section Meeting, 2002

4. Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. The role of biopsy laterality for T1c and T2 prostate cancer AUA Western Section Meeting, 2002

5. Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. The role of biopsy laterality for T1c and T2 prostate cancer Society of Urological Oncology, 2002

6. Freedland SJ, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH Database. Society of Urological Oncology, 2002

7. Freedland SJ, Aronson WJ, Presti JC Jr., Kane CJ, Terris MK, Elashoff D, and Amling CL. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH Database. AUA National Meeting, 2003

8. Freedland SJ, Aronson WJ, Presti JC Jr., Terris MK, Kane CJ, Dorey F, and Amling CL. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer AUA National Meeting, 2003

9. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer is a significant independent predictor of PSA recurrence following radical prostatectomy AUA National Meeting, 2003

10. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA Western Section Meeting, 2003

11. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson, WJ. Pre-operative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. AUA Western Section Meeting, 2003

12. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA Western Section Meeting, 2003

13. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. Society of Urological Oncology, 2003

14. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr., Dorey F, and Aronson, WJ. Pre-operative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade, and serum PSA. Society of Urological Oncology, 2003

15. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA Southeastern Section Meeting, 2004

16. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA Southeastern Section Meeting, 2004

17. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, and Terris MK. Obesity is an independent predictor of biochemical failure following radical prostatectomy. AUA National Meeting, 2004

18. Freedland SJ, Kane CJ, Presti JC Jr., Terris MK, Aronson WJ, and Amling CL. Do younger men have better biochemical outcomes following radical prostatectomy? AUA National Meeting, 2004

19. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. AUA National Meeting, 2004

20. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, and Presti JC Jr. Percent of prostate needle biopsy cores with cancer from the most involved side of the biopsy is a better predictor of PSA recurrence following radical prostatectomy than the total percent of cores with cancer. AUA National Meeting, 2004

21. Freedland SJ, Kane CJ, Terris MK, Presti JC Jr. , Trock B, and Amling CL. Men with normal pre-operative serum PSA values have better biochemical outcomes following radical prostatectomy. AUA Western Section Meeting, 2004

22. Freedland SJ, Presti JC Jr. , Amling CL, Kane CJ, Trock B, and Terris MK. Obesity and biochemical outcome following radical prostatectomy for organ-confined disease with negative surgical margins. AUA Western Section Meeting, 2004

23. Freedland SJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC Jr. , and Terris MK. Adult height predicts biochemical progression following radical prostatectomy among black men but not white men. AUA Western Section Meeting, 2004

24. Freedland SJ, Isaacs WB, Platz E, Terris M, Amling CL, Presti JC Jr. , and Kane CJ. Prostate size is inversely correlated with risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. AUA Western Section Meeting, 2004

25. Freedland SJ, Isaacs WB, Platz E, Presti JC Jr., Amling CL, Kane CJ, and Terris MK. Race, anthropomorphic measurements and prostate size. AUA Western Section Meeting, 2004

26. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Terris MK. Characteristics of Asian American Veterans Undergoing Radical Prostatectomy International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer. 2004, Tokyo, Japan

27. Kane CJ, Aronson WJ, Terris MK, Amling CL, Presti JC, and Freedland SJ. High-risk patients undergoing radical prostatectomy today are less high-risk than in the past. AUA National Meeting, 2005

28. Freedland SJ, Isaacs WB, Platz E, Terris M, Aronson WJ, Amling CL, Presti JC Jr. , and Kane CJ. Prostate size is inversely correlated with risk of high-grade, advanced cancer, and biochemical progression following radical prostatectomy. AUA National Meeting, 2005

29. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. Society of Urologic Oncology, 2005

30. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr., and Terris MK. Delay in receiving radical prostatectomy and risk of biochemical progression among men with low-risk prostate cancer. ASCO Prostate Cancer Symposium, 2006

31. Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. ASCO Prostate Cancer Symposium, 2006

32. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MT, and Presti JC Jr. Undergrading and overgrading of prostate needle biopsies: risk factors and clinical implications. AUA National Meeting, 2006

33. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti, JC, Jr., Amling CL, Terris MK, Aronson WA, Kane CJ, and Carroll PR. Multi-institutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence following radical prostatectomy. AUA National Meeting, 2006

34. Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. AUA National Meeting, 2006

35. Shah S, Freedland SJ, Presti JC Jr., Aronson WJ, Amling CL, Kane CJ, and Terris MK. Agent Orange exposure and risk of advanced disease and biochemical progression after radical prostatectomy AUA National Meeting, 2006

36. Scales CD Jr, Amling CL, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ, Freedland, SJ Can unilateral prostate cancer be reliably predicted based upon biopsy features? AUA National Meeting, 2006

37. Bastian PJ, Gonzalgo ML, Mangold LA, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Epstein JI, Partin AW, Freedland SJ. Pathological and biochemical outcomes after radical prostatectomy for men with a biopsy Gleason score of 8 to 10. AUA National Meeting, 2006

38. Terris MK, Freedland SJ, Platz EA, Presti JC Jr., Aronson WJ, Amling CL, and Kane CJ. Obesity, serum PSA, and prostate size: implications for prostate cancer detection. AUA Southeastern Section, 2006

39. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and Freedland SJ. Significance of the apical margin in radical prostatectomy ASCO Prostate Cancer Symposium, 2007

40. Bañez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and Freedland SJ. Can hemodilution explain the lower PSA concentrations among obese men? ASCO Prostate Cancer Symposium, 2007

41. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. ASCO Prostate Cancer Symposium, 2007

42. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and Freedland SJ. African American race, risk of biochemical recurrence, and PSADT after radical prostatectomy. ASCO Prostate Cancer Symposium, 2007

43. Freedland SJ, Hotaling JM, Fitzsimons NJ, Pesti JC Jr, Kane CJ, Terris MK, Aronson WJ, and Amling CL. PSA in the new millennium: still a good predictor of prostate cancer prognosis and treatment outcomes? ASCO Prostate Cancer Symposium, 2007

44. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and Freedland SJ. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score ASCO Prostate Cancer Symposium, 2007

45. Buschemeyer WC III, Hamilton RJ, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and Freedland SJ. Significance of the apical margin in radical prostatectomy AUA Southeastern Section, 2007

46. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. AUA Southeastern Section, 2007

47. Kang DE, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL, and Freedland SJ. Risk stratification of men with Gleason 7-10 tumors by primary and secondary Gleason score AUA Southeastern Section, 2007

48. Scales CD Jr, Amling CL, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ, Freedland, SJ Can unilateral prostate cancer be reliably predicted based upon biopsy features? AUA Southeastern Section, 2007

49. Hamilton RJ, Buschemeyer WC III, Terris MK, Aronson WJ, Kane CJ, Presti JC Jr, Amling CJ, and Freedland SJ. Significance of the apical margin in radical prostatectomy AUA National Meeting, 2007

50. Bañez LL, Hamilton RJ, Vollmer RT, Moul JW, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and Freedland SJ. Can hemodilution explain the lower PSA concentrations among obese men? AUA National Meeting, 2007

51. Buschemeyer WC III, Hamilton RJ, Amling CL, Kane CJ, Terris MK, Aronson WJ, Presti JC Jr, and Freedland SJ. Is a positive bladder neck margin truly a T4 lesion in the PSA era? Results from the SEARCH database. AUA National Meeting, 2007

52. Shah SR, Freedland SJ, Kane CJ, Aronson WJ, Presti JC Jr, Amling CL, and Terris MK. Agent Orange exposure among black men is a stronger predictor of PSA recurrence and rapid post-recurrence PSADT than among white men. AUA National Meeting, 2007

53. King KR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, and Presti JC Jr. The optimal timing, cutoff and method of calculation of preoperative PSA velocity to predict relapse after prostatectomy: a report from SEARCH database. AUA National Meeting, 2007

54. Nelles JL, Freedland SJ, Presti JC Jr, Terris MK, Aronson WJ, Amling CL, and Kane CJ. Nerve sparing does not increase the risk of biochemical recurrence AUA National Meeting, 2007

55. Hamilton RJ, Amling CL, Kane CJ, Aronson WJ, Terris MK, Presti JC Jr, and Freedland SJ. African American race, risk of biochemical recurrence, and PSADT after radical prostatectomy. AUA National Meeting, 2007

56. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki B, Thompson I, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, and Freedland SJ. Are the Partin tables accurate for African-American men in the United States? AUA National Meeting, 2007

57 Freedland SJ, Hamilton RJ, Aronson WJ, Terris MK, Pesti JC Jr, Amling CL, and Kane CJ. Obesity, risk of biochemical recurrence, and PSADT after radical prostatectomy. AUA National Meeting, 2007

58. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ, and Freedland SJ. What are the factors associated with a short PSA doubling time? – a report from the SEARCH database group. Society of Urologic Oncology, 2007

59. Klink JC, Bañez LL, Powell IP, Aronson WJ, Terris MK, Kane CJ, Amling CL and Freedland SJ. T1C Disease in black men: a more aggressive disease? Results from the SEARCH database group. Society of Urologic Oncology, 2007

60. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti Jr. JC, Amling CL, Kane CJ, and Freedland SJ. Obesity as a predictor of adverse outcome across black and white race. Results from the SEARCH database group. Society of Urologic Oncology, 2007

61. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, Moul JW, and Freedland SJ. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? Society of Urologic Oncology, 2007

62. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL, Moul JW, and Freedland SJ. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? ASCO GU Cancers, 2008

63. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti Jr. JC, Amling CL, Kane CJ, and Freedland SJ. Obesity as a predictor of adverse outcome across black and white race. Results from the SEARCH database group. ASCO GU Cancers, 2008

64. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ, and Freedland SJ. What are the factors associated with a short PSA doubling time? – a report from the SEARCH database group. ASCO GU Cancers, 2008

65. Jayachandran J, Bañez LL, Levy De, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, and Freedland SJ. Risk stratification for biochemical recurrence among men with positive surgical margins or extracapsular disease after radical prostatectomy ASCO GU Cancers, 2008

66 Scales Jr CD, Terris MK, Aronson WJ, Presti JC Jr., Kane CJ, Amling CL, Krupski TL, and Freedland SJ. Does practice reflect the evidence? Lymph node dissection with radical prostatectomy; results from the SEARCH Database. AUA Annual Meeting, 2008

67. Turley RS, Hamilton RJ, Terris MK, Kane, CJ, Aronson W, Presti JC Jr., Amling CL and Freedland SJ. Small TRUS volume predicts clinically significant Gleason score upgrading after radical prostatectomy AUA Annual Meeting, 2008

68. Teeter AE, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and Freedland SJ. Does early PSADT, calculated starting at the first detectable PSA after radical prostatectomy correlate with standard PSADT? Report from the SEARCH database group. AUA Annual Meeting, 2008

69. Bañez LL, Hamilton RJ, Aronson WJ, Terris MK, Presti JC Jr., Kane CJ, Amling CL and Freedland SJ. Higher cholesterol increases the risk of biochemical failure after radical prostatectomy: results from the search database group. AUA Annual Meeting, 2008

70. Teeter AE, Bañez LL, Aronson WJ, Presti JC Jr., Terris MK, Amling CL, Kane CJ and Freedland SJ. What are the factors associated with a short PSA doubling time? Report from the search database group. AUA Annual Meeting, 2008

71. Lin DW, Terris MK, Aronson WJ, Presti JC Jr., Kane CJ, Amling CL and Freedland SJ. Outcome among men with Pathological Gleason sum 8-10 prostate cancer at the time of radical prostatectomy AUA Annual Meeting, 2008

72. Jayachandran J, Bañez LL, Levy DL, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ and Freedland SJ. Risk stratification among men with positive surgical margins or extracapsular disease after radical prostatectomy AUA Annual Meeting, 2008

73. Kane CJ, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL and Freedland SJ. PSA Velocity (PSAV) to cancer-specific PSA (PSA(PCa)) ratio increases with higher Gleason score: results from the SEARCH Database AUA Annual Meeting, 2008

74. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling, CL, Kane CK, Sun L, Moul JW and Freedland SJ. Obesity as a predictor of adverse outcome across black and white race: results from the SEARCH and Duke Prostate center databases. AUA Annual Meeting, 2008

75. Kane CJ, Terris MK, Aronson WJ, Presti JC Jr., Amling CL and Freedland SJ. Outcomes after radical prostatectomy among men who are candidates for active surveillance AUA Annual Meeting, 2008

76. Klink JC, Bañez LL, Powell IJ, Aronson WJ, Terris MK, Kane CJ, Amling, CL and Freedland SJ. T1C disease in black men: a more aggressive disease AUA Annual Meeting, 2008

77. Freedland SJ, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL and Kane CJ. Over the last 15+ years, the percentage of men undergoing radical prostatectomy who are candidates for active surveillance has not changed AUA Annual Meeting, 2008

78. Freedland SJ, Moul JW, Sun L, Neville TB, Kaminski DA, Falvello VB, Terris MK, Aronson WJ, Presti, JC Jr., Amling CL, Kane CJ. Dynamic screening detects prostate cancer earlier and would lead to improved cancer control: results from the Duke Prostate center and the SEARCH database. AUA Annual Meeting, 2008

79. Bañez LL, Sun L, Aronson WJ, Terris MK, Presti JC Jr., Amling CL, Kane CJ, Moul JW and Freedland SJ. Is PSA a poor predictor of adverse pathology and biochemical failure following radical prostatectomy in obese men? AUA Annual Meeting, 2008

80. Schroeck F, Kattan M, Moul J, Aronson W, Presti Jr. J, Terris M, Kane C, Amling C, Sun L and Freedland SJ. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (RP). AUA Annual Meeting, 2009

81. Bañez L, Jayachandran J, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Association between statins, obesity and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. AUA Annual Meeting, 2009

82. Jayachandran J, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Diabetes and outcomes after radical prostatectomy- are results affected by obesity and race? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. AUA Annual Meeting, 2009

83. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Does PSADT after radical prostatectomy predict overall survival?—A report from the SEARCH Database Group. AUA Annual Meeting, 2009

84. Moreira D, Bañez L, Presti Jr. J, Aronson W, Terris M and Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy AUA Annual Meeting, 2009

85. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Natural history of persistently elevated PSA after radical prostatectomy AUA Annual Meeting, 2009

86. Moreira D, Jayachandran J, Bañez L, Kane C, Amling C, Stephenson A and Freedland SJ. Validation of Stephenson nomogram to predict PSA progression following salvage radiotherapy after radical prostatectomy AUA Annual Meeting, 2009

87. Bañez L, Moreira D, Krupski T, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and Freedland SJ. Predictors of castration resistant Prostate Cancer in men undergoing salvage androgen deprivation therapy- Results from the SEARCH Database. AUA Annual Meeting, 2009

88. Bañez L, Sun L, Trock B, Han M, Partin A, Aronson W, Terris M, Presti Jr. J, Kane C, Amling C, Moul J and Freedland SJ. Body mass index and prostate-specific antigen as a predictor of adverse pathology and biochemical recurrence following radical prostatectomy. AUA Annual Meeting, 2009

89. Hamilton R, Bañez L, Aronson W, Terris M, Kane C, Presti Jr. J, Amling C and Freedland SJ. Statin medication use and the risk of biochemical recurrence following radical prostatectomy AUA Annual Meeting, 2009

90. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Natural history of salvage radiotherapy for recurrent prostate cancer AUA Annual Meeting, 2009

91. Presti Jr. J, Terris M, Kane C, Amling C and Freedland SJ. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? AUA Annual Meeting, 2009

92. Bañez L, Presti Jr. J, Terris M, Aronson W, Kane C, Amling C and Freedland SJ. Do H2 blockers lower serum PSA results? Data from the SEARCH Database. AUA Annual Meeting, 2009

93. Bañez L, Terris M, Aronson W, Presti Jr. J, Kane C, Amling C and Freedland SJ. Race and time from diagnosis to radical prostatectomy: Does equal-access mean equal timely access to the operating room? Results from the SEARCH Database. ASCO GU Cancers, 2009

94. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Does early PSADT (ePSADT) after radical prostatectomy, calculated using PSA values starting with the first detectable PSA values, correlate with standard PSADT? A report from the SEARCH Database Group. ASCO GU Cancers, 2009

95. Teeter A, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Does PSADT after radical prostatectomy predict overall survival? A report from the SEARCH Database Group. ASCO GU Cancers, 2009

96. Moreira D, Bañez L, Amling C, Presti Jr. J, Terris M, Aronson W, Kane C and Freedland SJ. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy ASCO GU Cancers, 2009

97. Moreira D, Presti Jr. J, Aronson A, Terris M, Kane C, Amling C, Sun L, Moul J and Freedland SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: Results from the SEARCH and DPC Databases. Society of Urological Oncology, 2009

98. Schroeck F, Kattan M, Moul J, Aronson W, Presti Jr. J, Terris M, Kane C, Amling C, Sun L and Freedland SJ. Recalibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (RP). Society of Urological Oncology, 2009

99. Moreira D, Antonelli J, Presti Jr. J, Aronson W, Terris M, Kane C and Freedland SJ. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy ASCO GU Cancers, 2010

100. Teeter A, Presti J, Aronson W, Terris M, Amling C, Kane C and Freedland SJ. Does early PSA doubling time after radical prostatectomy correlate with overall survival? A report from the SEARCH database group. ASCO GU Cancers, 2010

101. Teeter A, Aronson W, Presti Jr. J, Terris M Amling C, Kane C and Freedland SJ. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more distant prostate cancer outcomes than BCR?- A report from the SEARCH Database group. AUA Annual Meeting, 2010

102. Moreira D, Antonelli J, Presti Jr. J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy AUA Annual Meeting, 2010

103. Freedland SJ, Terris M, Presti Jr. J, Kane C, Amling C and Aronson W. Race and long-term outcomes after radical prostatectomy AUA Annual Meeting, 2010

104. Moreira D, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Does being on ADT alter the ability of PSA and PSADT to predict a positive bone scan? Results from the SEARCH Database. AUA Annual Meeting, 2010

105. Bañez L, Gerber L, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and Freedland SJ. Does initiating statin therapy after radical prostatectomy reduce the risk for biochemical recurrence? Results from the SEARCH Database. AUA Annual Meeting, 2010

106. Teeter A, Aronson W, Presti Jr. J, Terris M, Amling C, Kane C and Freedland SJ. Does PSA doubling time after radical prostatectomy correlate with overall survival? A report from the SEARCH Database group. AUA Annual Meeting, 2010

107. Keto C, Bañez L, Aronson W, Terris M, Presti Jr. J, Amling C, Kane C and Freedland SJ. Prostate cancer specific and overall survival in men treated with early androgen deprivation therapy for PSA-only recurrence after radical prostatectomy Society of Urological Oncology, 2010

108. Thomas J, Presti Jr. J, Aronson W, Terris, Kane C, Amling C, Freedland SJ and Moreira D. Short time to PSA nadir after radical prostatectomy is associated with increased risk of biochemical recurrence Society of Urological Oncology, 2010

109. Moreira D, Bañez L, Aronson W, Terris M, Amling C, Kane C, Presti Jr. J and Freedland SJ. Low serum folate is a risk factor for biochemical recurrence after radical prostatectomy Society of Urological Oncology, 2010

110. Stroup S, Freedland SJ, Millard F, Terris M, Aronson W, Presti Jr. J, Amling C and Kane C. Presence of Gleason pattern 5 on biopsy: Subclassification of high risk patients from the SEARCH Database. Society of Urological Oncology, 2010

111. Ho T, Aronson W, Terris M, Presti Jr. J, Kane C, Amling C and Freedland SJ. Obese men are more likely to have higher PSA nadir values after radical prostatectomy (RP), though this does not explain the higher biochemical recurrence (BCR) rates ASCO GU Cancers, 2011

112. Ho T, Aronson W, Terris M, Presti J, Kane C, Amling C and Freedland SJ. Obese men are more likely to have higher PSA nadir values after radical prostatectomy (RP), tough this does not explain the higher biochemical recurrence (BCR) rates AUA National Meeting, 2011

113. Keto C, Kane C, Amling C, Presti J, Terris M, Aronson W and Freedland SJ. PSA nadir during androgen deprivation therapy predicts adverse prostate cancer specific outcomes AUA National Meeting, 2011

114. Keto C, Kane C, Amling C, Presti J, Terris M, Aronson W and Freedland SJ. Obesity is associated with castrate resistant disease and metastasis in men treated with androgen deprivation therapy (ADT) for PSA-only recurrence after radical prostatectomy (RP) AUA National Meeting, 2011

115. Kopp R, Stroup S, Gerber L, Freedland SJ, Terris M, Aronson W, Presti J Jr., Amling C, and Kane C. Do repeated prostate biopsies worsen the outcome among men with prostate cancer who have a radical prostatectomy? Results from the SEARCH database. AUA National Meeting, 2011

116. Bañez L, Gerber L, Aronson W, Terris M, Presti J, Kane C, Amling C and Freedland SJ. Risk for recurrent prostate cancer increases with cholesterol on a continuum in men with abnormal cholesterol levels- an update from the SEARCH Database. AUA National Meeting 2011

117. Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Predictors of prostate cancer-specific mortality in patients with residual disease after radical prostatectomy American Urological Association, 2011

118. Moreira D, Presti J, Aronson W, Terris M, Kane C, Amling C and Freedland SJ. Extracapsular extension predicts who achieve undetectable PSA after radical prostatectomy American Urological Association, 2011.

119. Punnen S, Freedland SJ, Presti J, Amling C, Terris M, Aronson W, Kane C, Carroll P, and Cooperberg M. Multi-institutional validation of UCSF cancer of the prostate risk assessment-postsurgical score for prediction of recurrence post radical prostatectomy. Society of Urologic Oncology, 2011

120. Keto C, Aronson W, Terris M, Presti J, Kane C, Amling C, and Freedland SJ. PSA NADIR during androgen deprivation therapy predicts adverse prostate cancer specific outcome Society of Urologic Oncology, 2011

121. Singh A, Freedland SJ, Gerber L, Aronson W, Terris M, Presti J, Amling C, Kane C, and Bañez, L. Is clinical stage T2C prostate cancer intermediate or high-risk disease? – Results from the SEARCH database. Society of Urologic Oncology, 2011

122. Keto C, Kane C, Terris M, Amling C, Aronson W, Presti J, and Freedland SJ. A nomogram predicting ADT failure for men starting androgen deprivation therapy before metastatic disease Society of Urologic Oncology, 2011

123. Singh A, Gerber L, Freedland SJ, Aronson W, Terris M, Presti J, Amling C, and Bañez L. Is clinical stage T2c prostate cancer intermediate – or high-risk disease? Results from the SEARCH database. GU ASCO Annual Meeting, 2012

124. Muller R, Presti J, Aronson W, Terris M, Kane C, Amling C, and Freedland SJ. Does salvage radiation therapy (SRT) change the biology of recurrent prostate cancer (PCa) based on PSA doubling times (PSADT)? Results from the SEARCH database. GU ASCO Annual Meeting, 2012

125. Freedland SJ, Thomas J, Keto C, Aronson W, Presti J, Kane C, Amling C, and Terris M. Obesity and risk of metastatic disease after radical prostatectomy: Results from SEARCH. Southeastern Section of AUA Annual Meeting, 2012

126. Chu DI, Moreira DM, Gerber L, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, and Freedland SJ. The effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access healthcare setting AUA Annual Meeting, 2012

127. Punnen S, Freedland SJ, Presti J Jr., Kane C, Amling C, Terris M, Aaronson W, Carroll P, and Cooperberg M. Multi-institutional validation of the CAPRA-S score to predict outcomes after radical prostatectomy. AUA Annual Meeting, 2012

128. Singh A, Freedland SJ, Gerber L, Aronson W, Terris M, Presti J, Amling C, and Bañez L. Should clinical stage T2c prostate cancer be classified as intermediate- or high-risk? Results from the SEARCH database. AUA Annual Meeting, 2012

129. Moreira D, Bañez L, Aronson W, Presti J Jr., Terris M, Kane C, Amling C, and Freedland SJ. Low serum folate is a risk factor for biochemical recurrence after radical prostatectomy AUA Annual Meeting, 2012

130. Abern M, Aronson W, Terris M, Presti J, Kane C, Amling C, and Freedland SJ. Delayed radical prostatectomy in Gleason 7 prostate cancer decreases time to biochemical recurrence AUA Annual Meeting, 2012

131. Muller R, Presti J Jr., Aronson W, Terris M, Kane C, Amling C, and Freedland SJ. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. AUA Annual Meeting, 2012

132. Tsivian M, Freedland SJ, Bañez L, Gerber L, Presti J Jr., Aronson W, Terris M, Kane C, Amling C, Moul J, and Polascik T. Unilateral prostate cancer: Analysis of predictors in SEARCH and Duke prostate center databases. AUA Annual Meeting, 2012

133. Brawer M, Cooperberg M, Freedland SJ, Swanson G, Stone S, Reid J, Gutin A, Carroll P, and Cuzick J. Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. SESAUA Annual Meeting, 2012

134. Brawer M, Cooperberg M, Freedland SJ, Swanson G, Stone S, Reid J, Gutin A, Carroll P and Cuzick J. Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. Society of Urologic Oncology, 2012

135. Muller R, Aronson W, Terris M, Kane C, Amling C, Presti J, Jr. and Freedland SJ. Salvage radiation therapy after recurrent prostate cancer: how early do we need to be? Society of Urologic Oncology, 2012

136. Brawer M, Cooperberg M, Freedland SJ, Swanson G, Stone S, Reid J, Gutin A, Carroll P and Cuzick J. Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. GU ASCO, 2013

137. Brawer M, Cuzick J, Cooperberg M, Swanson GP, Freedland SJ, Reid JE, Fisher G, Lanchbury JS, Gutin A, Stone S, Carroll P. Prolaris: A novel genetic test for prostate cancer prognosis. ASCO Annual Meeting, 2013

138. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy Society of Urologic Oncology, 2014

139. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Society of Urologic Oncology, 2014

140. Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Pathological Gleason 8-10: Do all men do poorly? Results from the SEARCH database. Society of Urologic Oncology, 2014

141. Simon R, Howard L, Freedland SJ, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Vidal A. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? SESAUA Annual Meeting, 2014

142. Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ, Vidal A. Pathological Gleason 8-10: Do all men do poorly? Results from the SEARCH database. SESAUA Annual Meeting, 2014

143. McGinley K, Sun X, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. SESAUA Annual Meeting, 2014

144. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Does larger tumor volume explain the higher PSA levels in black men with prostate cancer – results from the SEARCH Database. SESAUA Annual Meeting, 2014

145. McGinley K, Sun SX, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy SESAUA Annual Meeting, 2014

146. Moreira D, Howard L, Sourbeer K, Kundich R, Kane C, Aronson W, Terris M, Cooperberg M, Amling C, Freedland SJ. Predicting bone scan positivity in castration-resistant prostate cancer. AUA Annual Meeting, 2014

147. Fowke J, Howard L, Andriole G, Freedland SJ. Alcohol intake increase high-grade prostate cancer risk among men taking Dutasteride in the Reduce trial. AUA Annual Meeting, 2014

148. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Freedland SJ, Vidal AC. Metabolic syndrome components and prostate cancer risk: results from the Reduce study. AUA Annual Meeting, 2014

149. Ovadia AE, Abern MR, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Terris MK. Agent orange and long-term outcomes after radical prostatectomy. AUA Annual Meeting, 2014

150. Vidal AC, Williams C, Allott EH, Howard LE, Grant DJ, McPhail M, Sourbeer KN, Buffetta P, Hoyo C, Freedland SJ. Carbohydrate intake, Glycemic Index and prostate cancer risk. AUA Annual Meeting, 2014

151. Moreira D, Howard L, Sourbeer K, Kundich R, Kane C, Aronson W, Terris M, Cooperberg M, Amling C, Freedland SJ. Predictors of time to metastasis in non-metastatic castration-resistant prostate cancer. AUA Annual Meeting, 2014

152. Bishoff J, Freedland SJ, Gerber L, Tennstedt P, Welbourn W, Reid J, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury J, Sauter G, Brawer M, Stone S, Schlomm T. Prognostic utility of the Cell Cycle Progression (CCP) score generated from needle biopsy in men treated with prostatectomy. AUA Annual Meeting, 2014

153. Cooperberg M, Freedland SJ, Schlomm T, Reid J, Stone S, Brawer M. Predicting radical prostatectomy outcome: CCP-CR score outperforms primary Gleason Grade among men with clinical Gleason <7 WHO are upgraded to Gleason 7. AUA Annual Meeting, 2014 154. Moreira D, Andriole G, Castro-Santamaria R, Freedland SJ. Extension and severity of prostate inflammation and atrophy are independently associated with lower PSA levels in men undergoing prostate biopsy. AUA Annual Meeting, 2015

155. Fischer S, Simon R, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ, Vidal A. Pathologic Gleason 8-10: Do all men do poorly? results from the SEARCH database. AUA Annual Meeting, 2015

156. Zapata D, Howard LE, Frank J, Ross S, Hoyo C, Grant D, Freedland SJ, Vidal AC. Self-reported sexual function is associated with prostate cancer risk. AUA Annual Meeting, 2015

157. Guerrios L, Howard L, Sourbeer K, Arulraja E, Beverly D, Grant DJ, Hoyo C, Freedland S. Is BMI the best adiposity measure for prostate cancer risk? AUA Annual Meeting, 2015

158. Vidal AC, Howard LE, Kane CJ, Terris M, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese Castration-resistant prostate cancer patients may be at a lower risk of metastasis and all-cause mortality AUA Annual Meeting, 2015

159. Mendez M, Basset M, Abern M, Banez L, Ferrandino M, Robertson C, Freedland SJ, Inman B, Walter P, Moul J, Polascik T. Weighing in on active surveillance: impact of obesity on patient counseling. AUA Annual Meeting, 2015

160. Moreira D, Andriole G, Castro-Santamaria, Freedland SJ. Extension of baseline prostate and chronic inflammation is associated with lower incidence of prostate cancer on repeat biopsy. AUA Annual Meeting, 2015

161. Klaassen Z, Howard LE, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. The relationship of obesity, pathologic Gleason Grade and prostate cancer tumor volume at the time of radical prostatectomy- results from the SEARCH database. AUA Annual Meeting, 2015

162. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical Stage T2C prostate cancer intermediate or high-risk disease? AUA Annual Meeting, 2015

163. Wadhwa H, Terris M, Aronson W, Kane C, Amling C, Cooperberg M, Freedland SJ, Abern M. Long term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital (SERACH) Cohort. AUA Annual Meeting, 2015

164. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Does obesity modify the ability of pre-biopsy PSA to detect prostate cancer on repeat biopsy? results from the Reduce study. AUA Annual Meeting, 2015

165. Klaassen Z, Howard LE, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer- Results from the SEARCH database. AUA Annual Meeting, 2015

166. Klaassen Z, Howard LE, Moreira DM, Andriole GL, Terris MK, Freedland SJ. Are lower PSA levels in obese men due to hemodilution or low androgens? Results from Reduce. AUA Annual Meeting, 2015

167. Freedland SJ, Howard L, Amling C, Cooperberg M, Kane C, Terris M, Aronson W. Does early androgen deprivation therapy after biochemical recurrence following radical prostatectomy increase overall survival? results from SEARCH. AUA Annual Meeting, 2015

168. Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland SJ. Is computerized Tomography a necessary part of a prostate cancer metastatic workup? Results from SEARCH. AUA Annual Meeting, 2015

169. Hanyok B, Howard L, Amling C, Aronson W, Cooperberg M, Kane C, Terris M, Freedland SJ. When is an equivocal bone scan not really equivocal? Results from SEARCH. AUA Annual Meeting, 2015

170. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAID and risk of high-grade prostate cancer: results from the Reduce study. AUA Annual Meeting, 2015

171. Mithal P, Howard L, Aronson W, Terris M, Cooperberg M, Kane C, Amling C, Freedland SJ. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from SEARCH. AUA Annual Meeting, 2015

172. McGinley K, Sun X, Howard L, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) dataase. AUA Annual Meeting, 2015

173. Simon R, Howard L, Freedland SJ, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Vidal A. Adverse pathology yet undetectable ultrasensitive PSA: Is adjuvant radiation really necessary? AUA Annual Meeting, 2015

174. Simon R, Howard L, Moreira D, Freedland S, Roehrborn C, Vidal A. Peak urine flow predicts development of symptomatic BPH in men with mild to no urinary symptoms: Results from Reduce. AUA Annual Meeting, 2015

175. Bishoff J, Freedland SJ, Schlomm T, Reid J, Brawer M, Stone S, Cuzick J. The CCP score provides significant prognostic information in Gleason score< 7 patients. AUA Annual Meeting, 2016 176. Feng T, Sun X, Howard L, Vidal A, Moreira D, Castro-Santamaria R, Andriole G, Freedland SJ. Metformin use and risk of prostate cancer: Results from the Reduce study. AUA Annual Meeting, 2016

177. A prospective randomized trial of dietary carbohydrate restriction for men initiating androgen deprivation therapy: Carbohydrate and prostate study 1 (CAPS1). AUA Annual Meeting, 2016

178. Daskivich T, Skarecky D, Ahlering T, Freedland SJ. Comorbidity status as a predictor of high-grade disease in men with prostate cancer. AUA Annual Meeting, 2016

179. Stroup S, Moreira D, Chen Z, Howard L, Terris M, Aronson W, Cooperberg M, Amling C, Kane C, Freedland SJ. Biopsy-Detected Gleason pattern 5 is a particularly strong preoperative predictor of recurrence, metastasis, and mortality in men with high-risk prostate cancer. AUA Annual Meeting, 2016

180. Moreira D, Nickel JC, Andriole G, Castro-Santamaria R, Freedland SJ. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer. AUA Annual Meeting, 2016

181. Ross A, Den R, Yousefi K, Trock B, Davicioni E, Tosoian J, Thompson D, Choeurng V, Hadda Z, Tran P, Trabulsi E, Gomelia L, Lallas C, Abdollah F, Feng F, Dicker A, Freedland SJ, Karnes J, Schaeffer E. Efficacy of early and delayed radiation in a prostatectomy Cohort adjusted for genomic and clinical risk. AUA Annual Meeting, 2016

182. Nickel JC, Freedland SJ, Roehrborn C, Castro-Santamaria R, Morreira D. Impact of prostate inflammation on 4 year incidence, severity, AUR and symptom progression of Benign Prostatic Hyperplasia. AUA Annual Meeting, 2016

183. Feng T, Simon R, Howard L, Vidal A, Moreira D, Castro-Santamaria R, Andriole G, Roehrborn C, Freedland SJ. PSA predicts development of incident lower urinary tract symptoms: Results from the Reduce study. AUA Annual Meeting, 2016

184. Feng T, Howard L, Vidal A, Moreira D, Castro-Santamaria R, Andriole G, Freedland SJ. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduce study. AUA Annual Meeting, 2016

185. Moreira D, Andriole G, Castro-Santamaria R, Freedland SJ. Dutasteride is associated with reduced risk of transrectal prostate biopsy -associated urinary tract infection and related hospitalizations: results from the reduce study. AUA Annual Meeting, 2016

186. Moreira D, Howard L, Hanyok B, Kadiyala V, Kuang J, Whitney C, Wilks F, Kane C, Terris M, Amling C, Cooperberg M, Aronson W, Freedland SJ. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. AUA Annual Meeting, 2016

187. Moreira D, Andriole G, Castro-Santamaria R, Freedland SJ. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on Repeat study. AUA Annual Meeting, 2016

188. Stroup S, Chen Z, Howard L, Freedland SJ, Moreira D, Terris M, Aronson W, Cooperberg M, Kane C. Radical prostatectomy and the effect of close surgical margins: analysis from the SEARCH database. AUA Annual Meeting, 2016

189. Macias E, Corcoran D, Chi J, Freedland SJ. Genomic screen identifies actionable kinases for obesity driven prostate cancer. AUA Annual Meeting, 2016

190. Allot E, Masko E, Macias E, Pelton K, Solomon K, Mostaghel E, Thomas G, Freeman M, Pizzo S, Freedland SJ. Serum cholesterol levels impact tumor progression in a ptendeficient transgenic mouse model of prostate cancer. AUA Annual Meeting, 2016

191. Allot E, Macias E, Thomas G, Hursting S, Freedland SJ. Carbohydrate restriction opposes tumor-promoting effects of obesity in the HI-MYC transgenic mouse model of prostate cancer. AUA Annual Meeting, 2016

192. Nickel JC, Freedland SJ, Castro-Santamaria R, Moreira D. Chronic prostate inflammation predicts symptom progression in chronic prostatitis/chronic pelvic pain patients. AUA Annual Meeting, 2016

193. Feng T, Howard L, Vidal A, Moreira D, Castro-Santamaria R, Andriole G, Freedland SJ. The effect of Statins on development of significant lower urinary tract symptoms: Results from the Reduce study. AUA Annual Meeting, 2016

194. Klaassen Z, Howard L, De Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. AUA Annual Meeting, 2016

195. Michael S. Leapman, Stephen J. Freedland, William J Aaronson, Christopher J. Kane, Martha K. Terris, Christopher L. Amling, Peter Carroll, Matthew R. Cooperberg. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Genitourinary Cancers Symposium,ASCO,2016 .

196. Zachary Klaassen, Lauren E. Howard, Amanda de Hoedt; Christopher L. Amling, MD; William J. Aronson,Matthew R. Cooperberg,Christopher J. Kane, Martha K. Terris, and Stephen J. Freedland. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant .Society of Urologic Oncology Annual Meeting,2016 .

197. Zachary Klaassen, Lauren E. Howard, Amanda de Hoedt; Christopher L. Amling, MD; William J. Aronson,Matthew R. Cooperberg,Christopher J. Kane, Martha K. Terris, and Stephen J. Freedland. Validation of the 2015 prostate cancer prognostic grade groups for predicting long-term oncologic outcomes in a shared equal access health system. Society of Urologic Oncology Annual Meeting,2016 .

198. Leapman M, Freedland SJ, Aronson W, Kane C, Terris M, Walker K, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among african-american and caucasian men with low-risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. AUA Annual Meeting, 2016

199. McGinley K, Howard L, Chen Z, Aronson W, Terris M, Kane C, Amling C, Cooperberg M, Freedland SJ. Are we operating on who we should? the changing charcteristics of radical prostatectomy patients: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. AUA Annual Meeting, 2016

200. Ariel Schulman, Lauren Howard, Kae Jack Tay, Rajan Gupta, Efrat Tsivian, Christopher Amling, William Aronson, Matthew Cooperberg. Validation of the prostate cancer prostate cancer prognostic grade groups for predicting long-term oncologic outcomes in a shared equal access health system. AUA Annual Meeting,2017 .

201. Zachary Zumsteg, Zinan Chen, Lauren Howard, Christopher Amling, William Aronson, Matthew Cooperberg, Christopher Kane, Martha Terris. Novel risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy. AUA Annual Meeting, 2017 .

202. Colette Whitney, Lauren Howard, Edwin Posadas, Christopher Amling, William Aronson, Matthew Cooperberg, Christopher Kane, Martha Terris. In men with castration-resistant prostate cancer visceral metastases predicts shorter overall survival: what predicts visceral metastases?. AUA Annual Meeting,2017 .

203. Stephanie L. Skove, Lauren E. Howard, Jean-Alfred Thomas, William J. Aronson, Martha K. Terris, Matthew R. Cooperberg, Christopher J. Kane, Christopher L. Amling. Timing of psa nadir after radical prostatectomy and risk of biochemical recurrence: does it matter?. AUA Annual Meeting,2017 .

204. Lauren Howard, Daniel Moreira, Amanda De Hoedt, William Aronson, Christopher Kane, Christopher Amling, Matthew Cooperberg, Martha Terris. What are the best cut-points for psa doubling time in men with non-metastatic castration-resistant prostate cancer?. AUA Annual Meeting,2017 .

205. Anna Teeter, Kagan Griffin, Lauren Howard, William Aronson, Martha Terris, Christopher Kane, Christopher Amling, Matthew Cooperberg. Does early psadt (epsadt) after radical prostatectomy, calculated prior to psa recurrence, correlate with prostate cancer (pc) outcomes?.AUA Annual Meeting,2017 .

206. Colette Whitney, Lauren Howard, Stephen Freedland, Christopher Amling, William Aronson, Matthew Cooperberg, Christopher Kane, Martha Terris. Impact of age, comorbidity, and psa doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.AUA Annual Meeting,2017 .

207. Ariel Schulman, Lauren Howard, Kae Jack Tay, Rajan Gupta, Efrat Tsivian, Christopher Amling, William Aronson, Matthew Cooperberg. Analysis of the predictive utility of prognostic grade groups (pgg) for predicting perioperative oncologic outcomes of radical prostatectomy in the shared equal access regional cancer hospital (search) database.AUA Annual Meeting,2017 .

208. Anna Teeter, Xizi Sun, Lauren Howard, William Aronson, Christopher Kane, Christopher Amling, Matthew Cooperberg, Martha Terris. Do sicker people have worse prostate cancer-specific outcomes after radical prostatectomy?.AUA Annual Meeting,2017 .

209. Ariel Schulman, Lauren Howard, Kae Jack Tay, Efrat Tsivian1, Rajan Gupta, Christopher Amling, William Aronson,Matthew Cooperberg, Christopher Kane, Martha Terris,Stephen Freedland, Thomas Polascik. Analysis of the predictive utility of prostate prognostic grade groups for predicting perioperative oncologic outcomes in a shared equal access health system . Southeastern Section of the AUA, Inc. Annual Meeting,2017 .

210. Brandee Branche, Lauren Howard, Robert Hamilton, William Aronson, Martha Terris, Matthew Cooperberg, Christopher Amling, Christopher Kane. Obesity, risk of biochemical recurrence, and PSADT after radical prostatectomy: Results from the SEARCH database. AUA Annual Meeting,2018 .

211. Emma Allott, Lauren Howard, William Aronson, Martha Terris, Christopher Kane, Christopher Amling, Matthew Cooperberg, Stephen Freedland. Statin use is associated with improved prostate cancer-specific outcomes in white but not black men initiating androgen deprivation therapy. AUA Annual Meeting,2018 .

212. Drew Moghanaki, Lauren Howard, Amanda De Hoedt, William Aronson, Christopher Kane, Christopher Amling, Matthew Cooperberg, Martha Terris. Validity of the National Death Index to accurately code the date of death and deaths from prostate cancer, in men having undergone prostatectomy. AUA Annual Meeting,2018 .

213. Kae Jack Tay, Thomas Polascik, Lauren Howard, Joseph Salama, Ariel Schulman, Zinan Chen, Christopher Amling, William Aronson. Salvage radiation therapy for recurrent prostate cancer: Can the prognosis grade group system inform treatment timing? AUA Annual Meeting,2018 .

214. Ariel Moradzadeh, Lauren Howard, William Aronson, Martha Terris, Matthew Cooperberg, Christopher Amling, Christopher Kane, Stephen Freedland. The impact of comorbidity and age on timing of androgen deprivation therapy in men with biochemical recurrence after radical prostatectomy. AUA Annual Meeting,2018 .

215. Shweta Dambal, Lauren Howard, Emma Allott, William Aronson, Christopher Kane, Christopher Amling, Matthew Cooperberg, Martha Terris. Serum lipid profile at time of androgen deprivation therapy and risk of castration-resistant prostate cancer: Results from the SEARCH database. AUA Annual Meeting,2018 .

216. Devin Patel, Shalini Jha, Lauren Howard, Christopher Amling, William Aronson, Matthew Cooperberg, Christopher Kane, Martha Terris. The impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from SEARCH. AUA Annual Meeting,2018 .

Back to Top

Papers are continually published using the SEARCH Database. For questions or collaboration opportunities, please contact us.